Cerulean Pharma Company Profile (NASDAQ:CERU)

About Cerulean Pharma

Cerulean Pharma logoCerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CERU
  • CUSIP:
Key Metrics:
  • Previous Close: $1.01
  • 50 Day Moving Average: $1.247
  • 200 Day Moving Average: $2.286
  • 52-Week Range: $0.92 - $4.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.71
  • P/E Growth: 0.000
  • Market Cap: $28.67M
  • Outstanding Shares: 27,384,000
  • Beta: 2.05
Profitability:
  • Return on Equity: -107.96%
  • Return on Assets: -67.35%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 3.38%
  • Quick Ratio: 3.38%
Additional Links:
Companies Related to Cerulean Pharma:

Analyst Ratings

Consensus Ratings for Cerulean Pharma (NASDAQ:CERU) (?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $8.63 (723.78% upside)

Analysts' Ratings History for Cerulean Pharma (NASDAQ:CERU)
Show:
DateFirmActionRatingPrice TargetDetails
8/30/2016Barclays PLCLower Price TargetOverweight$5.00 -> $2.00View Rating Details
8/21/2016Canaccord GenuityReiterated RatingBuy$29.00 -> $20.00View Rating Details
8/18/2016WedbushDowngradeOutperform -> NeutralView Rating Details
8/18/2016Roth CapitalReiterated RatingBuy$9.00 -> $2.50View Rating Details
8/18/2016Leerink SwannDowngradeOutperform -> Market Perform$8.00 -> $1.50View Rating Details
8/18/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
3/9/2016JPMorgan Chase & Co.Boost Price TargetMarket Outperform$9.00 -> $16.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Cerulean Pharma (NASDAQ:CERU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016        
8/4/2016Q216($0.48)($0.40)ViewN/AView Earnings Details
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details
8/6/2015Q215($0.43)($0.37)ViewN/AView Earnings Details
3/19/2015($0.36)($0.37)ViewN/AView Earnings Details
11/13/2014($0.32)($0.28)ViewN/AView Earnings Details
8/12/2014($0.36)($0.34)ViewN/AView Earnings Details
5/29/2014($3.52)($3.70)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cerulean Pharma (NASDAQ:CERU)
Current Year EPS Consensus Estimate: $-1.64 EPS
Next Year EPS Consensus Estimate: $-1.48 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.38)($0.40)
Q2 20162($0.49)($0.48)($0.49)
Q3 20163($0.50)($0.38)($0.45)
Q4 20163($0.52)($0.39)($0.46)
Q1 20171($0.40)($0.40)($0.40)
Q2 20171($0.40)($0.40)($0.40)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerulean Pharma (NASDAQ:CERU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cerulean Pharma (NASDAQ:CERU)
Insider Ownership Percentage: 28.60%
Institutional Ownership Percentage: 33.18%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28View SEC Filing  
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00View SEC Filing  
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00View SEC Filing  
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50View SEC Filing  
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00View SEC Filing  
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90View SEC Filing  
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16View SEC Filing  
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00View SEC Filing  
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00View SEC Filing  
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.00View SEC Filing  
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.00View SEC Filing  
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.00View SEC Filing  
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.00View SEC Filing  
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.16View SEC Filing  
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.36View SEC Filing  
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.85View SEC Filing  
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.00View SEC Filing  
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.03View SEC Filing  
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.50View SEC Filing  
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.44View SEC Filing  
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cerulean Pharma (NASDAQ:CERU)
DateHeadline
News IconLatest Analyst Ratings For Cerulean Pharma Inc. (CERU) - The De Soto Edge (NASDAQ:CERU)
desotoedge.com - September 30 at 9:10 AM
einnews.com logoEpizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and Quality Assurance (NASDAQ:CERU)
www.einnews.com - September 29 at 9:02 AM
247wallst.com logoKey FDA Decisions and Trial Results Expected in October (NASDAQ:CERU)
247wallst.com - September 29 at 9:02 AM
News IconPenny Stock Investors are Growing Curious About Cerulean Pharma Inc. (NASDAQ:CERU) - Duncan Research (NASDAQ:CERU)
www.duncanindependent.com - September 28 at 4:01 PM
News IconBiotech Stocks Worth Chasing: Cerulean Pharma Inc. (CERU), Amgen Inc. (AMGN) - The Independent Republic (NASDAQ:CERU)
theindependentrepublic.com - September 28 at 4:01 PM
News IconInterested Penny Stock Investors Keen on Shares of Cerulean Pharma Inc. (NASDAQ:CERU) - Duncan Research (NASDAQ:CERU)
www.duncanindependent.com - September 28 at 4:01 PM
News IconBiotech Stocks Worth a Closer Look: Heat Biologics, Inc. (NASDAQ:HTBX), Cerulean Pharma Inc. (NASDAQ:CERU) - The Voice Registrar (NASDAQ:CERU)
voiceregistrar.com - September 28 at 4:01 PM
News IconTraders Observable Stock: Royal Bank Scotland plc (NYSE:RBS) , Cerulean Pharma Inc. (NASDAQ:CERU) - Wall Street Times (press release) (NASDAQ:CERU)
www.wallstreetnews24.com - September 27 at 8:45 AM
News IconRectal Cancer - Pipeline Review, H2 2016: New research report available at Fast Market Research (NASDAQ:CERU)
reports.pr-inside.com - September 26 at 8:53 AM
News IconKeen Investors Find News on Cerulean Pharma Inc. (NASDAQ:CERU) - Duncan Research (NASDAQ:CERU)
www.duncanindependent.com - September 24 at 8:24 AM
News IconBrokerages Set Cerulean Pharma Target Price at $14.60 (NASDAQ:CERU) - Petro Global News 24 (NASDAQ:CERU)
petroglobalnews24.com - September 22 at 4:21 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Portola Pharma, bluebird bio, Auris Medical, and Cerulean Pharma - PR Newswire (press release) (NASDAQ:CERU)
www.prnewswire.com - September 22 at 4:21 PM
News IconEarnings According to Analysts for Cerulean Pharma Inc. (NASDAQ:CERU)? - Frisco Fastball (NASDAQ:CERU)
friscofastball.com - September 22 at 4:21 PM
News IconUnder the Microscope, Zeroing in at Cerulean Pharma Inc. (NASDAQ:CERU) - Duncan Research (NASDAQ:CERU)
www.duncanindependent.com - September 22 at 4:21 PM
News IconBiotech Stocks on Investors' Radar -- Portola Pharma, bluebird bio, Auris Medical, and Cerulean Pharma (NASDAQ:CERU)
www.kait8.com - September 22 at 9:47 AM
News IconPenny Stock Investors Take an Interest in Cerulean Pharma Inc. (NASDAQ:CERU) - Duncan Research (NASDAQ:CERU)
www.duncanindependent.com - September 21 at 8:11 AM
investorplace.com logo26 Biotechnology Stocks to Sell Now - Investorplace.com (NASDAQ:CERU)
investorplace.com - September 19 at 4:58 PM
News IconStock Update: Estimates & Target in Focus for Cerulean Pharma Inc ... - Frisco Fastball (NASDAQ:CERU)
friscofastball.com - September 16 at 6:38 AM
News IconReport explores the 2016 H2 metastatic renal cell carcinoma pipeline market key companies analysis (NASDAQ:CERU)
www.whatech.com - September 12 at 4:01 PM
News IconCerulean Pharma, Inc. Clinical Review, Industry Study, Market Research and Forecast 2016 - 2020 - Medgadget (blog) (NASDAQ:CERU)
www.medgadget.com - September 5 at 3:58 PM
News IconCerulean (CERU) Kidney Cancer Drug Disappoints in Phase II – Yahoo Finance (NASDAQ:CERU)
baetrice.org - August 31 at 4:05 PM
finance.yahoo.com logoBarclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial (NASDAQ:CERU)
finance.yahoo.com - August 31 at 8:57 AM
kcregister.com logoTop Wall Street Stories: Cerulean Pharma Inc. (NASDAQ:CERU ... - KC Register (NASDAQ:CERU)
www.kcregister.com - August 29 at 3:32 PM
kcregister.com logoMarket Movers: Cerulean Pharma Inc. (NASDAQ:CERU), ECA Marcellus Trust I (NYSE:ECT), Advanced Micro Devices ... - KC Register (NASDAQ:CERU)
www.kcregister.com - August 29 at 8:54 AM
kcregister.com logoStocks Swings: Cerulean Pharma Inc. (NASDAQ:CERU), Ascendis Pharma A/S (NASDAQ:ASND), ConocoPhillips ... - KC Register (NASDAQ:CERU)
www.kcregister.com - August 20 at 9:05 AM
insidermonkey.com logoCerulean Pharma Inc (CERU): What’s Next? (NASDAQ:CERU)
www.insidermonkey.com - August 19 at 4:49 PM
streetinsider.com logoCerulean Pharma (CERU) to Cut Workforce by 48% (NASDAQ:CERU)
www.streetinsider.com - August 19 at 11:42 AM
reuters.com logoBRIEF-Cerulean Pharma says reducing workforce by about 48 pct (NASDAQ:CERU)
www.reuters.com - August 18 at 8:49 PM
publicnow.com logoCerulean Announces Reduction in Force (NASDAQ:CERU)
www.publicnow.com - August 18 at 8:48 PM
streetinsider.com logoCerulean Pharma (CERU) Says CRLX101 Combo Phase 2 Missed ... - StreetInsider.com (NASDAQ:CERU)
www.streetinsider.com - August 18 at 3:26 PM
rttnews.com logoJNP Will Bleed On Failed Trial, CERU Crashes, FDA Says No To PTLA (NASDAQ:CERU)
www.rttnews.com - August 18 at 11:52 AM
thestreet.com logoCerulean Pharma (CERU) Stock Tumbles on Lead Kidney Cancer Drug Failure (NASDAQ:CERU)
www.thestreet.com - August 18 at 11:52 AM
247wallst.com logoThursday’s Top Health Care Stocks Punishing Investors (NASDAQ:CERU)
247wallst.com - August 18 at 11:52 AM
reuters.com logoBRIEF-Cerulean Pharma reports Phase 2 results from clinical trial of CRLX101 and Avastin combination (NASDAQ:CERU)
www.reuters.com - August 17 at 9:37 PM
4-traders.com logoCERULEAN PHARMA INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:CERU)
www.4-traders.com - August 17 at 9:37 PM
News IconDisappointing Trial Outcome for Cerulean Pharma (CERU); Insiders Confidence in Cobalt Intl Energy (CIE) (NASDAQ:CERU)
galaxystocks.com - August 17 at 9:37 PM
streetinsider.com logoCerulean Pharma (CERU) Says CRLX101 Combo Phase 2 Missed Primary Endpoint (NASDAQ:CERU)
www.streetinsider.com - August 17 at 4:18 PM
finance.yahoo.com logoCerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin® Combination in Relapsed Renal Cell Carcinoma (NASDAQ:CERU)
finance.yahoo.com - August 17 at 4:18 PM
biz.yahoo.com logoCERULEAN PHARMA INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CERU)
biz.yahoo.com - August 17 at 4:18 PM
finance.yahoo.com logoCERULEAN PHARMA INC. Financials (NASDAQ:CERU)
finance.yahoo.com - August 13 at 4:10 PM
finance.yahoo.com logoEdited Transcript of CERU earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:CERU)
finance.yahoo.com - August 5 at 4:11 PM
sg.finance.yahoo.com logoCerulean reports 2Q loss (NASDAQ:CERU)
sg.finance.yahoo.com - August 4 at 9:52 PM
finance.yahoo.com logoCerulean Reports Second Quarter 2016 Corporate Highlights and Financial Results (NASDAQ:CERU)
finance.yahoo.com - August 4 at 4:18 PM
biz.yahoo.com logoQ2 2016 Cerulean Pharma Inc Earnings Release - Time Not Supplied (NASDAQ:CERU)
biz.yahoo.com - August 4 at 12:44 PM
ftsenews.co.uk logoCerulean Pharma Inc. (CERU) Updated Price Targets - FTSE News ... - FTSE News (NASDAQ:CERU)
www.ftsenews.co.uk - August 1 at 4:05 PM
ftsenews.co.uk logoNew Broker Ratings For Cerulean Pharma Inc. (CERU) - FTSE ... - FTSE News (NASDAQ:CERU)
www.ftsenews.co.uk - July 29 at 4:14 PM
sbwire.com logoKidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 - New Market Study Published (NASDAQ:CERU)
www.sbwire.com - July 28 at 12:55 PM
publicnow.com logoCerulean to Host Second Quarter 2016 Conference Call on August 4 (NASDAQ:CERU)
www.publicnow.com - July 28 at 7:08 AM
kcregister.com logoBiotech Decliners: Heat Biologics, Inc. (NASDAQ:HTBX), Zafgen, Inc. (NASDAQ:ZFGN), Cerulean Pharma Inc ... - KC Register (NASDAQ:CERU)
www.kcregister.com - July 23 at 8:25 AM
News IconIncreased Volatility Noted on Shares of: Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily (NASDAQ:CERU)
www.engelwooddaily.com - July 23 at 8:25 AM

Social

Cerulean Pharma (NASDAQ:CERU) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff